Its either now or never as it reaches previous high testBreak the candle and move on to the 52-week test. This has been turbulent up and down, and there is no escaping the current path to its momentum unless we see a break in structure.
another flush from a promising start 450 not farThe stock swings have been trying to position themselves into an upswing trending faction. However, they have failed to materialize and have LS from making new highs, an early indication that things may need re-evaluation.
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH
(1/9)
Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀
(2/9) – REVENUE RUSH
• Q4 Haul: $ 2.91B—16% jump from l
$VRTX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:VRTX after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 85.71%.
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity.
The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addi
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associ
Reversal on Vertex Pharmaceuticals. VRTXMean reversion strategy in a fade for the most recent rally. Here, we are betting that the rally, now in OBOS, will not cross the most recent high of highs. More specifically, that the price action will not exceed one std deviation of the vWAP value. There are divergences on the indicators below to
$VRTX, Long, TP>25% NASDAQ:VRTX , Long, TP>25%
Fundamentally the stock is good.
Choose an entry point and do not forget about a protective order if you are trading with leverage.
Don't risk it if you're not sure.
Good luck to everyone.
VRTX"A quick trade for traders based on a classic, well-known pattern: Symmetrical Triangle. Entry at $500, stop loss at $460. First target between $527.5 _ $535. Second target between $544 _ $549."
VRTXThe VRTX stock has broken the ascending channel and successfully retested it. It is now ready to be sold with a first target between $404.60 and $403, and a second target of $375.50. The stop loss is at $500.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VRTX is featured.
